Science & Enterprise subscription

Follow us on Twitter

  • A medical software team designed a mobile app that records and analyzes a person's sounds and sleep positions to de… https://t.co/NB99HQUWpC
    about 8 hours ago
  • New post on Science and Enterprise: Mobile App Screens for Sleep Apnea https://t.co/N8gTn2zWhe #Science #Business
    about 8 hours ago
  • Reported in Science & Enterprise on 6 May ... Coronavirus Testing the Cheap, Simple Way https://t.co/WqyoIhGjre
    about 11 hours ago
  • A company discovering therapeutic antibodies identified antibodies considered particularly effective in neutralizin… https://t.co/cHHeuebOv4
    about 1 day ago
  • New post on Science and Enterprise: Biotech IDs Potent Covid-19 Antibodies https://t.co/kDv6E821aA #Science #Business
    about 1 day ago

Please share Science & Enterprise

Recap – Editas Medicine Advances Crispr Therapy

Crispr genome edits illustration

(NIH.gov)

2 Dec. 2018. While much the world watched, and disapproved of, a Chinese researcher editing the genomes of embryos leading to the birth of twins, Editas Medicine in Cambridge, Massachusetts received the go-ahead to conduct a clinical trial using the genome editing technique Crispr. On Friday, the Food and Drug Administration, in an approved investigational new drug application, authorized Editas to test Crispr as a treatment for a rare inherited eye disease known as Leber congenital amaurosis type 10.

Here’s what else we reported on last week:

*     *     *

Please share Science & Enterprise ...

Comments are closed.